A single-molecule triple receptor agonist acting on GLP-1, GIP and glucagon receptors. The most requested compound in current metabolic research.
A dual GIP and GLP-1 receptor agonist. The compound that established dual agonism as more effective than GLP-1 alone in metabolic research models.
Retatrutide and tirzepatide, the multi-receptor incretin agonists. One is an approved medicine in its pharmaceutical form; the other is in phase 3. The research-grade compounds here are neither. Every product page lists the compound's specifications, storage conditions, stability notes derived from its sequence, verified references with a one-line summary of each, and the third-party certificate for the lot in stock where one exists. For how the members of this group compare, read the GLP-1 family comparison.
Identity data for every compound is on the peptide reference table; how to read a certificate is on the certificate guide.